<DOC>
	<DOC>NCT01365117</DOC>
	<brief_summary>Phase 1 clinical trial to evaluate insulin exposure using different formulations of Technosphere Insulin Inhalation Powder using the Gen2 inhaler in healthy normal volunteers.</brief_summary>
	<brief_title>Pharmacokinetic Study in Healthy Volunteers</brief_title>
	<detailed_description>Phase 1, single-center, open-label, randomized, crossover clinical trial to evaluate insulin exposure using the 3 U/mg and 4 U/mg Technosphere Insulin Inhalation Powder formulations administered using the Gen2 inhaler in 31 healthy volunteers. Drop outs will be replaced. Each subject will undergo a screening visit and either 4 or 5 days of in clinic stay and dosing, depending on randomization schedule.</detailed_description>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Nonsmoking (within the last 6 months) men and women aged 18 to 45 years who are considered healthy Body mass index (BMI) &lt; 32 kg/m2 FEV1 â‰¥ 80% of the Third National Health and Nutrition Examination Survey (NHANES III) predicted Preexisting asthma or chronic obstructive pulmonary disease (COPD) History of coronary artery disease, peripheral vascular disease, or congestive heart failure Blood donation within the previous 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>